DBV Technologies | DBVT - Ordinary Share Capital

Stock Price
19.59
Daily Change
-0.25 -1.26%
Monthly
-4.95%
Yearly
76.49%
Q2 Forecast
19.28

DBV Technologies reported $136.82M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amarin USD 20.81M 13K Dec/2025
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
DBV Technologies USD 136.82M 51.98K Sep/2025
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Galectin Therapeutics USD 61K 0 Dec/2023
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Insmed USD 216.52M 2.27M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Neurocrine Biosciences USD 100.6M 500K Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026